Abbreviations & Acronyms GCNIS = germ cell neoplasia in situ Kitl = ligand for KIT receptor PGC = primordial germ cell TGCT = testicular germ cell tumor Abstract: The development of the human gonads is tightly regulated by the correct sequential expression of many genes and hormonal activity. Disturbance of this regulation does not only prevent proper development of the gonads, but it also contributes to the development of testicular germ cell tumors. Recent genetic studies, especially genome-wide association studies, have made great progress in understanding genetic susceptibility. Although there is strong evidence of inherited risks, many environmental factors also contribute to the development of testicular germ cell tumors. Histopathological studies have shown that most testicular germ cell tumors arise from germ cell neoplasia in situ, which is thought to be arrested and transformed primordial germ cells. Seminoma has features identical to germ cell neoplasia in situ or primordial germ cells, whereas non-seminoma shows varied differentiation. Seminomas and embryonic cell carcinomas have the feature of pluripotency, which is thought to be the cause of histological heterogeneity and mixed pathology in testicular germ cell tumors. Testicular germ cell tumors show high sensitivity to chemotherapies, but 20-30% of patients show resistance to standard chemotherapy. In the present review, the current knowledge of the epidemiological and genomic factors for the development of testicular germ cell tumors is reviewed, and the mechanisms of resistance to chemotherapies are briefly mentioned.
Introduction
TGCTs are the most common malignancy in young adults. TGCTs have continued to increase during the past several decades in most populations. 1 The incidence of TGCT differs among ethnic groups. 1 It is highest in North European countries, such as Norway and Denmark, and lowest in African and Asian countries. 1 The familial risks of TGCT are much higher than those of most other cancers. The risks of the brothers of affected men are estimated to be five-to 19-fold higher, and the sons of affected men have an estimated risk that is two-to fourfold higher than other men. [2] [3] [4] These facts point strongly to the importance of hereditary factors in the development of TGCT.
In contrast, the fact that there have been increases of TGCT incidence over only a few decades suggests the existence of exogenous risk factors. 1 Consistent with this trend, although the incidence of TGCT is approximately twofold more frequent in Norway than in Sweden, despite the fact that these countries are geographically very close to each other, genetic analysis has not found any differences between these countries. 5 Furthermore, in a survey of immigrants, it was reported that the incidence of TGCT approaches that of the migration destination in the second generation of immigrants. 6 These facts suggest that environmental factors contribute to the incidence of TGCT. 5 The mortality rate of TGCT has improved worldwide from 1970 onwards, likely due to cisplatin-based chemotherapy. However, 20-30% of patients show resistance to standard chemotherapy, and a new approach based on the understanding of mechanisms underlying this situation is crucial.
Testicular differentiation and a model for TGCT Testicular germ cell tumors and germ cell neoplasia in situ
Histological studies showed atypical lesions in the testes of TGCT patients, but these lesions were considered to be degenerating malignant neoplasm cells or scattered tumor cells in spermatic cords. 7, 8 In 1972, Skakkebaek reported that embryonal cell carcinomas occurred in infertile men who underwent testicular biopsy that showed atypical lesions in the testes. 9 Based on this finding, he proposed the hypothesis that TGCTs arise from GCNIS.
Gonadal development
The widely accepted hypothesis for the origin of GCNIS is that they arise from PGCs or gonocytes whose maturation is disturbed (Fig. 1) .
PGCs arise from the epiblast, and migrate to the genital ridge and become gonocytes. This migration is controlled by KITLG-KIT signaling. 10 PGCs and gonocytes are characterized by the expression of stem cell factor or pluripotency markers, such as KIT, NANOG, POU5F1 (OCT3/4) and AP2c. [11] [12] [13] [14] While forming bipotential gonads in the genital ridge, PGCs and gonocytes are surrounded by supporting cells. Differentiation into testes or ovaries is determined by the presence or absence of SRY. 15, 16 The expression of SRY induces expression of a key transcription factor, SOX9, that directs the fate of the supporting cells into the Sertoli cell lineage.
17 SOX9 induces expression of many genes related to Sertoli cell proliferation and differentiation. 18 Regulated by SRY and SOX9, Sertoli cells start to form tight and adherent junctions, which is crucial to forming testis cords to support testis differentiation. 19 Subsequently, gonocytes begin to differentiate into spermatogonia, and Sertoli cells organize the niche to support spermatogonial stem cell self-renewal and spermatogonia differentiation. 20 Along with spermatogonia differentiation, the expressions of pluripotency markers, such as KIT, NANOG and OCT3/4, are gradually suppressed while these cells acquire the expression of some germ cellspecific genes, such as VASA, MAGE-4A and TSPY. 14, 21, 22 Dynamic epigenetic changes occur during normal development of germ cells, and expressions of these genes are tightly controlled by epigenomic mechanisms, such as DNA methylation and microRNA. [23] [24] [25] [26] 
PGCs and GCNIS
Histopathological findings have shown many similarities among TGCTs and their precursor cells. KIT expression in TGCTs was first described in 1991, and subsequent studies showed that KIT was highly expressed in GCNIS, PGCs and fetal gonocytes, although it is usually undetectable in spermatogonia in the adult testis. 27 In addition, in the studies of disorders of sex development, Rajpert-De Meytes et al. found that continuous high expression of KIT was detected in atypical fetal gonads. 28 Thus, the fact that KIT expression is essential for the survival of PGCs led to the hypothesis that disturbed gonadal development might cause the transformation of germ cells.
Consistent with this hypothesis, pathological evaluation showed that the expressions of the stem cell factor, KIT; the pluripotency markers, OCT3/4, NANOG and AP2c; and placental/germ cell alkaline phosphatase were detected in GCNIS, similar to the expressions of these markers in PGCs or gonocytes, 27, 29, 30 and GCNIS also has identical genomic imprinting and gene expression to gonocytes, 31 supporting the hypothesis that GCNIS is an arrested and transformed gonocyte. 31 
Origin of TGCT subtypes
Most TGCTs that arise in adolescents and young adults are thought to be tumors derived from GCNIS. These tumors can be subclassified into two groups: seminomas and non-seminomas. Seminomas have features similar to their origin, GCNIS or PGCs, whereas non-seminomas show varied differentiation. Seminomas and embryonic cell carcinomas, the malignant counterparts of embryonic stem cells, have features of pluripotency. Other types of non-seminomas, such as teratomas, yolk sack tumors and choriocarcinomas, are considered to be differentiated from embryonic cell carcinoma. The histological heterogeneity of TGCTs is attributed to their pluripotency.
In contrast to the tumors in adolescents and young adults, spermatocytic seminomas that usually occur in relatively elderly men arise from pre-meiotic germ cells, 32, 33 whereas non-seminomas in young children arise from embryonic stem cells or early PGCs. 34 
Epidemiological risk factors
Many epidemiological surveys have shown associations between several medical disorders and the incidence of TGCT. These disorders include previous TGCT in the contralateral testis, cryptorchidism, hypospadias and impaired spermatogenesis (Table 1) .
Recurrence in the contralateral testis
The incidence of metachronous germ cell tumor in the contralateral testis ranges from 1 to 5% in men affected by TGCTs, [35] [36] [37] [38] indicating that the relative risk of developing a germ cell tumor is approximately 25-fold higher in patients with a history of TGCT than in age-matched populations. 39 The risk of contralateral TGCTs is lower in patients with non-seminoma than with seminoma, consistent with the lower risk of patients with younger age at first TGCT diagnosis.
TGCTs and testicular dysgenesis syndrome
It is believed that PGCs or gonocytes are susceptible to environmental events, as genomic imprinting by DNA methylation is totally erased in these cells. Thus, development of TGCT is believed to start at a very early stage of fetal testicular development, and is affected by a series of genetic and environmental factors.
Carlsen et al. reported a decreased sperm count and increased male reproductive malformations, such as cryptorchidism, hypospadias and testicular tumor, over a period of 50 years. 40 Subsequently, Sharpe and Skakkebaek also showed that estrogens in the environment abolished the normal development of embryonic male reproductive organs, resulting in an increase in cryptorchidism and hypospadias in newborns, and a decrease in the number of spermatozoa or an increase in TGCTs in young men. 41 Based on accumulated experimental results and epidemiological evidence, these urogenital disorders and TGCT as symptoms of testicular dysgenesis syndrome might be the result of disruption of fetal development due mainly to adverse environmental factors. 42 This concept was supported by subsequent studies that reported that the concentrations of organic pollutants accumulating in the body were high in mothers of patients with TGCT, 43 and androgen/estrogen levels in pregnant women were also associated with TGCT development. 44 
Effects of hormone-disrupting chemicals and endogenous hormones
From these results, the influence of endocrine-disrupting chemicals, which bind to the estrogen or androgen receptors and act as estrogen agonists or androgen antagonists, on the development of male reproductive organs has attracted a great deal of interest. 45 Thus, endocrine disruptors, especially organochlorine compounds that have been widely used as anti-malarials with long half-lives and show toxicity, have been hypothesized to be a cause of testicular dysgenesis syndrome including TGCT. 46 A review of these compounds
showed an association between exposure to p,p 0 -DDE, cis-nonachlor, and trans-nonachlor and TGCT, although no endocrine disruptor showed sufficient evidence of an association with undescended testis, hypospadias and decreased spermatogenesis. 46 The effects of endogenous hormones on the incidence of TGCT have also been analyzed. Several studies showed that higher follicle-stimulating hormone and lower testosterone levels were detected in men with TGCT than in control men. 47 In contrast, TGCT is rarely observed in men with hypogonadotropic hypogonadism, even though cryptorchidism is observed at a high rate. 48 The theory that the initiation of TGCT is affected by the in utero environment has also led to considerable interest in perinatal factors, such as birthweight, gestational age, maternal age and birth order.
Many studies showed that birthweight 49 and its related factor, short gestational age, were associated with the incidence of TGCT. 50 Birth order and young maternal age have been reported to be linked to TGCT risks in some studies, but not all. These associations may be due to higher estrogen levels in younger mothers. 51 Other perinatal factors, such as bleeding and threatened miscarriage, 52 hormone use during pregnancy, 52 previous inguinal hernia, and sibship size, might also be associated with TGCT and have been found to be risk factors for TGCT. 50 
Genomic risk factors Chromosomal imbalance
Tumor-specific patterns of chromosomal imbalances characterize most kinds of cancers and allow one to find the genes that have been dysregulated by such imbalances. To analyze chromosomal imbalances in TGCT, many comparative genomic hybridization/studies have been carried out.
The most characteristic chromosomal imbalance associated with TGCT is gain of chromosome 12, usually in the form of an isochromosome, i(12p) chromosome. 53, 54 Furthermore, comparative genomic hybridization studies have shown that focal amplification of 12p11.2-p12.1, which includes the KRAS locus, could be observed in the absence of i(12p) chromosome.
55-57
Mutations related to TGCT KRAS encodes a GTPase that activates downstream targets, including the MAPK pathway and the PI3K-AKT pathway. 58 Activating KRAS mutations leads to hyperactivation of these pathways, and they are associated with the initiation of tumorigenesis in many cancers. 59 In fetal development, KIT-RAS signaling plays an important role in the migration of PGCs, but this signaling is gradually suppressed during differentiation. 22 Although most TGCTs show the gain of chromosome 12p, some studies have reported that 12p gain was not detected in GCNIS lesions associated with invasive TGCT. 60, 61 Consistent with these results, gain of KRAS was not found in GCNIS adjacent to TGCTs with upregulation of KRAS due to copy number gain. 57, 62 These results suggest that gain of 12p is an essential factor for TGCTs to acquire invasive ability. Other genes at 12p include NANOG, STELLA and CCND2, and they could contribute to TGCT development. NANOG and STELLA are essential factors to acquire pluripotency, and play an important role in embryonic stem cell self-renewal, whereas CCND2 controls the cell cycle.
Other than KRAS, the well-known mutated oncogene found in TGCT is KIT. KIT encodes tyrosine kinase transmembrane receptor and plays crucial roles in testicular development, as described above. Somatic activating mutations in KIT are observed in up to 25% of seminoma cases, 62-64 although they are not usually detected in non-seminomas. 64 Some studies using next-generation sequencing technology have been carried out in TGCT. 65, 66 These studies showed that TGCT had a markedly low mutation rate compared with other types of malignant tumors, and they showed a relatively homogeneous profile despite their heterogeneous histological features. 66 This supports the hypothesis that TGCTs share identical oncogenic pathways and differentiation occurs as a later event, which might also explain the mixed pathology observed in TGCTs. 66 Although these studies have identified novel mutations, the mutation rate was correlated with patient age, suggesting that most mutations were passenger mutations that accumulate with aging in the precursor cells transformed in the early stage of in utero development. 66 
Mutations associated with disorders of sex development
Patients with disorders of sex development, a term defined by the Consensus Statement on Management of Intersex Disorders in 2006, show a varying degree of atypical genital development in relation to genetic or gonadal sex, and some of these disorders are high-risk for TGCT. 67 Various kinds of mutations in sex differentiation-associated genes, such as SRY, SOX9, NR5A1, GATA4, MAP3k1 and DMRT1 are found in disorders of sex development patients, emphasizing the importance of sex differentiation-related pathways in TGCT development. [68] [69] [70] [71] [72] Susceptibility loci found in genome-wide association studies Although the accumulated evidence has shown increased risks of TGCT in family members of affected men, linkage analysis and candidate gene approaches have made little progress in the identification of TGCT-specific genetic risks. The risk locus that traditional linkage analysis identified was only gr/gr deletion on the Y chromosome, which is associated with azoospermia, although this deletion is identified in just 2-3% of TGCT cases. 66, 73 In contrast, genome-wide association studies have had remarkable success in identifying genetic risks associated with TGCT and have identified more than 40 risk loci (Fig. 2) . 74 These studies have shown that common allele variations in KITLG, known as stem cell factor, which encodes Kitl, is the strongest genetic risk factor for TGCT. 75 In a mouse model, Kitl controls PGC development by regulating proliferation, migration and survival of these cells. 76 As delayed differentiation of PGCs or gonocytes is associated with the development of TGCT, these results strongly suggest that KITLG plays a crucial role in TGCT tumorigenesis. Interestingly, the frequency of the risk variation of KITLG is higher in European ancestry populations than in African ancestry populations. As KITLG has also been reported to have a role in determining the level of pigmentation, 77 the difference in the inherited variation of KITLG could partially explain the significant differences of TGCT incidence among ethnic groups. 75 The other susceptibility loci for TGCT are found near the genes linked with KITLG-KIT signaling, such as SPRY4 (5p31), and BAK1 (5q31). 74, 78, 79 SPRY4 inhibits KITLG-KIT-MAPK signaling, and BAK1, which is repressed by KITLG-KIT signaling, encodes pro-apoptotic proteins and promotes apoptosis by suppressing the function of anti-apoptotic proteins, and MAPKs are the downstream target of KITLG-KIT signaling. Thus, the presence of susceptibility loci in these genes associated with KITLG-KIT signaling supports the importance of this pathway as a risk factor for TGCTs. Although Kit mutations are predominantly observed in seminomas, these genotypes in KITLG and SPRY4 are associated with both seminomas and non-seminomas. 75 Not surprisingly, many other risk loci were found in sex determination-related gene regions, such as DMRT1 (9q24), GATA4 (8p23), DAZL (3p24) and PRDM14 (8q13). 74, 78, 80, 81 DMRT1 encodes a transcriptional factor. High expression of this gene is associated with testicular differentiation, and low expression is related to ovarian differentiation. 82 GATA4 encodes a transcription factor that is essential for normal gonadal development through regulating the expressions of sex determination-related genes, such as SRY, SOX9 and DMRT1.
79,83-85 DAZL modulates PGCs, and mutation of this gene is associated with severe spermatogenic failure.
86
PRDM14 plays a critical role in the maintenance of pluripotency in embryonic stem cells through regulation of epigenetic reprogramming, and it regulates early differentiation of PGCs. 87 Many susceptibility loci that are associated with the incidence of TGCT are identified near these genes, and this provides strong support to the hypothesis that TGCTs occur due to disturbed differentiation of PGCs or gonocytes.
Through genome-wide association studies analyses, risk loci have been identified near the genes associated with telomerase activity, such as TERT-CLPTM1L (5p15) and its related genes, such as ATF7IP (12p13) and PITX1 (5q31). 80 TERT encodes the catalytic subunit of the telomerase reverse transcriptase, which adds short nucleotide repeats to chromosomal ends. The expression of TERT is usually absent in somatic cells, although it is expressed in the process of embryonal development. Reactivation of TERT, which enables cells to overcome senescence and achieve proliferation without restriction, is one of the hallmarks of cancer, and its activity is observed in up to 90% of malignancies. In TGCT, TERT expression and telomerase activity are high in seminomas, whereas they are low in differentiated TGCTs, such as teratomas. 88, 89 Epigenetic changes and TGCT subtypes Different histological subtypes of TGCT have different gene expression profiles, although these tumors have homogeneous genetic profiles. 90 These differences are believed to be caused by epigenetic regulation. The most studied epigenetic mechanism is regulation by DNA methylation. The patterns of DNA methylation differ among the TGCT subgroups: seminomas show quite low levels of DNA methylation similar to PGCs or GCNIS, whereas non-seminomas show different extents of DNA methylation associated with the degree of differentiation, such as hypermethylation in teratomas, yolk sac tumors and choriocarcinomas, whereas embryonic cell carcinomas show an intermediate pattern. [91] [92] [93] The differences in DNA methylation patterns in TGCT subtypes support the model that seminoma and embryonic cell carcinoma arise from GCNIS, and other subtypes of non-seminomas are differentiated from embryonic cell carcinomas; 94 this might also explain the coexistence of TGCT subtypes in the same patient.
TGCT characteristics and sensitivity to chemotherapy
The development of cisplatin-based chemotherapy achieved remarkable progress in the treatment of TGCTs. The low number of mutations in TGCTs might contribute to their sensitivity to such treatments. 66 Some other malignant tumors with low mutation rates, such as pediatric medulloblastoma, pediatric acute lymphoblastic leukemia and acute myeloid leukemia, show the same characteristic in terms of sensitivity to chemotherapy. 65 Two characteristics that contribute to sensitivity to chemotherapy are thought to be a hypersensitive apoptotic response and a reduction of proficiency in repairing DNA damage. 95 Treatment with cisplatin induces DNA damage, which leads to activation of the DNA damage response in tumor cells. Due to the low rate of mutations in DNA damage response-related genes, such as p53 and Rb, in TGCT, DNA damage with cisplatin easily induces apoptosis due to increased expression of proapoptotic molecules, Puma and Noxa. These responses are mediated not only by p53, but also by OCT4, which is highly expressed in seminomas and embryonal cell carcinomas. 95 
Resistance and the mismatch repair system
The mismatch repair system is a system for recognizing basepairing errors in DNA. Loss or a defect of the mismatch repair system leads to microsatellite instability, a form of genomic hypermutability. Like microsatellite instability in colorectal cancer (Lynch syndrome), microsatellite instability in TGCT is correlated with BRAF V600E mutation and is associated with treatment failure in TGCT patients. [96] [97] [98] Both mismatch instability and mutated BRAF are correlated with decreased hMLH1 protein and promoter hypermethylation. 99 Thus, these results suggest that genetic tests are useful for predicting resistance in TGCT.
Resistance and epigenetic regulations
The relationship between differentiation with epigenetic alteration and resistance to cisplatin has been known for several decades. Seminomas are characterized by their low DNA methylation status, and they also show less frequent resistance to chemotherapy than non-seminomas. An in vitro study showed that treatment with a differentiation-inducing factor, retinoic acid, led to downregulation of OCT4, Noxa and Puma. 100 The same reactions have been observed with hypoxia, which is a well-known factor related to resistance to chemotherapy. 101 The expression of OCT4 does not directly affect the activity of p53, but it regulates the expression of Noxa.
102
Depletion of OCT4 decreases cisplatin hypersensitivity through suppression of Noxa to a similar extent as Noxa depletion, suggesting that the contribution of OCT4 to sensitivity to chemotherapy is due to the control of Noxa expression. 102 The study also showed that, although OCT4-depleted cells showed resistance to cisplatin, a protease inhibitor could induce apoptosis in these cells with the accumulation of both Noxa and p53, suggesting that this accumulation plays a central role in the death of TGCTs. 102 However, clinically, yolk sac tumors and choriocarcinomas, which have low expressions of OCT4, showed sensitivity to cisplatin-based chemotherapy, as seen in embryonic cell carcinoma. Further studies are required to clarify the discrepancy between in vitro studies and clinical outcomes.
Based on the relationship between DNA methylation status and sensitivity to chemotherapy, some demethylation agents have been analyzed in TGCT cell lines. [103] [104] [105] These studies showed that exposure to 5-azacytidine restored the response to cisplatin and led to the expression of p53 target genes that are suppressed by DNA methylation, and this effect was largely dependent on the expression levels of DNMT3B. 103, 105 DNMT3B expression is higher in embryonal cell carcinoma than in seminoma, suggesting that it might regulate differentiation from embryonal cell carcinoma into other types of non-seminoma and contribute to resistance to chemotherapy. 94 
Conclusion
Development of TGCTs is strongly associated with gonadal development and sex differentiation. TGCTs maintain the genomic and epigenomic features of their precursor cells, and these unique features are also associated with their sensitivity to chemotherapy. Thus, understanding these features will help to understand the mechanisms of treatment resistance, and to identify new therapeutic targets to improve the clinical care of patients with TGCTs.
